Most ladies taking relugolix for uterine fibroid-related heavy menses obtain amenorrhea

Might 11, 2022

1 min learn


Lukes AS, et al. Summary 78. Introduced at: ACOG Annual Scientific & Scientific Assembly; Might 6-8, 2022; San Diego.

Disclosures: Lukes experiences consulting for AbbVie and Myovant, and being a principal investigator for AbbVie, Bayer, Gynesonics, Merck, Myovant and ObsEva.

We had been unable to course of your request. Please attempt once more later. For those who proceed to have this situation please contact [email protected].

SAN DIEGO — About 70% of ladies with uterine fibroid-related heavy menstrual bleeding who took relugolix mixture remedy skilled amenorrhea, in line with information offered on the ACOG Annual Scientific & Scientific Assembly.

“Of the remaining girls who had both cyclic or irregular bleeding, roughly half had recognizing or mild or average bleeding that was thought of inside the regular vary for menstrual blood loss,” Andrea S. Lukes, MD, MHSc, FACOG, principal investigator of the examine and founding father of Carolina Ladies’s Analysis and Wellness Heart in Durham, North Carolina, informed Healio.

Most women with uterine fibroids and heavy menstrual bleeding experienced amenorrhea when taking relugolix. Source: Adobe Stock
Most ladies with uterine fibroids and heavy menstrual bleeding skilled amenorrhea when taking relugolix. Supply: Adobe Inventory

Lukes and colleagues analyzed the bleeding patterns and depth of 327 premenopausal girls with uterine fibroid-related heavy menstrual bleeding recorded in each day diary entries for 52 weeks or by the tip of therapy with relugolix combination therapy. Mixture remedy included once-daily relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg.

Researchers included girls who accomplished 24 weeks of therapy in both LIBERTY 1 or 2 examine — each of which had been section 3, placebo-controlled research that decided that relugolix mixture remedy improved heavy menses associated to uterine fibroids — who agreed to take part within the current 28-week extension examine.

Throughout the examine inhabitants, 163 girls continued relugolix mixture remedy and 164 switched to mixture remedy after having taken placebo throughout LIBERTY 1 or 2.

Information revealed that 86.5% of ladies who continued mixture remedy and 75% who switched to mixture remedy responded to therapy by the tip of the examine, with 70.6% and 57.9% reaching amenorrhea, respectively.

Amongst those that continued therapy, 15 (9.2%) girls skilled cyclic bleeding, with 5 (3.1%) experiencing continued heavy menstrual bleeding. Moreover, 33 (20.2%) girls who continued therapy had irregular bleeding, with 10 (6.1%) having continued heavy menstrual bleeding.

Amongst girls who switched from placebo, 25 (15.2%) skilled cyclic bleeding, with 15 (9.1%) experiencing continued heavy menses. Additionally, 44 (26.8%) girls skilled irregular bleeding, 9 (5.5%) of whom continued to expertise heavy menstrual bleeding.

Andrea S. Lukes, MD, MHSc, FACOG

Andrea S. Lukes

“Ladies with heavy menstrual bleeding related to uterine fibroids who take relugolix mixture remedy for a 12 months may have adjustments of their bleeding sample related to the therapy impact of the drug,” Lukes mentioned. “These information counsel that almost all of ladies ought to anticipate to see amenorrhea.”



Leave a Reply